APO RESEARCH · REPORT
Pneumococcal Vaccine
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
Product & engineering
Understand the product.
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
Selected research
Industry Research
Pneumococcal Vaccine Industry Research Report 2026
Market perspective
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
Read the full market overview
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
Report Scope
This report quantifies the global Pneumococcal Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pneumococcal Vaccine Market by Company
Pfizer
GSK
MSD
Sanofipasteur
CDIBP
Pneumococcal Vaccine Segment by Type
PPSV 23
PCV 7/13
PCV 10
Pneumococcal Vaccine Segment by End User
Child
Adult
Pneumococcal Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Pneumococcal Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Pneumococcal Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Pneumococcal Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by end user, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- PPSV 23
- PCV 7/13
- PCV 10
Applications
- Child
- Adult
Companies covered
- Pfizer
- GSK
- MSD
- Sanofipasteur
- CDIBP
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Pneumococcal Vaccine Market Size (2021-2032)
- 2.2.2 Global Pneumococcal Vaccine Sales (2021-2032)
- 2.2.3 Global Pneumococcal Vaccine Market Average Price (2021-2032)
- 2.3 Pneumococcal Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 PPSV 23
- 2.3.3 PCV 7/13
- 2.3.4 PCV 10
- 2.4 Pneumococcal Vaccine by End User
- 2.4.1 Market Value Comparison by End User (2021 VS 2025 VS 2032)
- 2.4.2 Child
- 2.4.3 Adult
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Pneumococcal Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Pneumococcal Vaccine Sales (K Doses) of Manufacturers (2021-2026)
- 3.3 Global Pneumococcal Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Pneumococcal Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Pneumococcal Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Pneumococcal Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Pneumococcal Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Pneumococcal Vaccine, Established Date
- 3.9 Global Pneumococcal Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Pfizer
- 4.1.1 Pfizer Company Information
- 4.1.2 Pfizer Business Overview
- 4.1.3 Pfizer Pneumococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Pfizer Pneumococcal Vaccine Product Portfolio
- 4.1.5 Pfizer Recent Developments
- 4.2 GSK
- 4.2.1 GSK Company Information
- 4.2.2 GSK Business Overview
- 4.2.3 GSK Pneumococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GSK Pneumococcal Vaccine Product Portfolio
- 4.2.5 GSK Recent Developments
- 4.3 MSD
- 4.3.1 MSD Company Information
- 4.3.2 MSD Business Overview
- 4.3.3 MSD Pneumococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 MSD Pneumococcal Vaccine Product Portfolio
- 4.3.5 MSD Recent Developments
- 4.4 Sanofipasteur
- 4.4.1 Sanofipasteur Company Information
- 4.4.2 Sanofipasteur Business Overview
- 4.4.3 Sanofipasteur Pneumococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sanofipasteur Pneumococcal Vaccine Product Portfolio
- 4.4.5 Sanofipasteur Recent Developments
- 4.5 CDIBP
- 4.5.1 CDIBP Company Information
- 4.5.2 CDIBP Business Overview
- 4.5.3 CDIBP Pneumococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 CDIBP Pneumococcal Vaccine Product Portfolio
- 4.5.5 CDIBP Recent Developments
5 Global Pneumococcal Vaccine Market Scenario by Region
- 5.1 Global Pneumococcal Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Pneumococcal Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Pneumococcal Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Pneumococcal Vaccine Sales by Region: 2027-2032
- 5.3 Global Pneumococcal Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Pneumococcal Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Pneumococcal Vaccine Revenue by Region: 2027-2032
- 5.4 North America Pneumococcal Vaccine Market Facts & Figures by Country
- 5.4.1 North America Pneumococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Pneumococcal Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Pneumococcal Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Pneumococcal Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Pneumococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Pneumococcal Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Pneumococcal Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Pneumococcal Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Pneumococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Pneumococcal Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Pneumococcal Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Pneumococcal Vaccine Market Facts & Figures by Country
- 5.7.1 South America Pneumococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Pneumococcal Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Pneumococcal Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Pneumococcal Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Pneumococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Pneumococcal Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Pneumococcal Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Pneumococcal Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Pneumococcal Vaccine Sales by Type (2021-2032) & (K Doses)
- 6.1.2 Global Pneumococcal Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Pneumococcal Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Pneumococcal Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Pneumococcal Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Pneumococcal Vaccine Price by Type (2021-2032)
7 Segment by End User
- 7.1 Global Pneumococcal Vaccine Sales by End User (2021-2032)
- 7.1.1 Global Pneumococcal Vaccine Sales by End User (2021-2032) & (K Doses)
- 7.1.2 Global Pneumococcal Vaccine Sales Market Share by End User (2021-2032)
- 7.2 Global Pneumococcal Vaccine Revenue by End User (2021-2032)
- 7.2.1 Global Pneumococcal Vaccine Sales by End User (2021-2032) & (US$ Million)
- 7.2.2 Global Pneumococcal Vaccine Revenue Market Share by End User (2021-2032)
- 7.3 Global Pneumococcal Vaccine Price by End User (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Pneumococcal Vaccine Value Chain Analysis
- 8.1.1 Pneumococcal Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Pneumococcal Vaccine Production Mode & Process
- 8.2 Pneumococcal Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Pneumococcal Vaccine Distributors
- 8.2.3 Pneumococcal Vaccine Customers
9 Global Pneumococcal Vaccine Analyzing Market Dynamics
- 9.1 Pneumococcal Vaccine Industry Trends
- 9.2 Pneumococcal Vaccine Industry Drivers
- 9.3 Pneumococcal Vaccine Industry Opportunities and Challenges
- 9.4 Pneumococcal Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst